For people with multiple sclerosis (MS), a higher burden of comorbidity is associated with worse clinical outcomes, according ...

Patients will be able to get a 10 minute injection of the Roche drug, instead of an hours-long infusion. Novartis already has ...

Researchers have identified biomarkers that can predict disease progression in multiple sclerosis, which could lead to the ...

Rutgers Health researchers will enroll patients with primary or secondary progressive multiple sclerosis (p-MS) patients to see if an engineered immune cell therapy can halt the progression of the ...

Genentech’s newly approved multiple sclerosis (MS) injection takes about 10 minutes to administer, dramatically reducing the ...

Patients were recruited at the Corinne Goldsmith Dickinson Center for Multiple Sclerosis through a collaboration with Ilana Katz Sand, MD, Associate Director of the Center for Global Development ...

The Food and Drug Administration (FDA) has approved Ocrevus Zunovo™ (ocrelizumab and hyaluronidase-ocsq) for the treatment of relapsing form of multiple sclerosis (MS), to include clinical isolated ...

These findings showed that patients receiving continuous Zeposia treatment for up to five years experienced ... and cognitive decline,” said Jeffrey Cohen, MD, Mellen Center for Multiple Sclerosis, ...

A groundbreaking study has unveiled a critical issue of therapeutic inertia in treating women with multiple sclerosis (MS ... of initiating or intensifying treatment for a medical condition ...

The research, presented today at ECTRIMS 2024, is the result of efforts by the Alliance for Research in Hispanic MS (ARHMS) Consortium and is the first large-scale study to identify ancestry-specific ...

Higher comorbidity burden among people with multiple sclerosis (MS) was associated with worse clinical outcomes, pooled trial ...